Insiders · VYNE

VYNE insider transactions

VYNE Therapeutics Inc. (VYNE) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for VYNE

• 23d
  SEC Form 4 filed by Zeronda Tyler

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 23d
  SEC Form 4 filed by Stuart Iain

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 23d
  SEC Form 4 filed by Harsch Mutya

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 23d
  SEC Form 4 filed by Domzalski David

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 110d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,684 shares, decreasing direct ownership by 3% to 416,208 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 110d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,448 shares, decreasing direct ownership by 2% to 115,239 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 110d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 7,858 shares, decreasing direct ownership by 7% to 103,795 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 110d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,579 shares, decreasing direct ownership by 3% to 125,905 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 131d
  SEC Form 4 filed by Director Barbari Sharon

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 131d
  SEC Form 4 filed by Director Basta Steven L

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 131d
  SEC Form 4 filed by Director Little Elisabeth Sandoval

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 131d
  SEC Form 4 filed by Director Lepore Patrick G

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 205d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,453 shares, decreasing direct ownership by 2% to 117,687 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 205d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,676 shares, decreasing direct ownership by 3% to 428,892 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 205d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,420 shares, decreasing direct ownership by 3% to 111,653 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 205d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,581 shares, decreasing direct ownership by 3% to 129,484 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 297d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,420 shares, decreasing direct ownership by 3% to 115,073 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 297d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,453 shares, decreasing direct ownership by 2% to 120,140 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 297d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,581 shares, decreasing direct ownership by 3% to 133,065 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 297d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,676 shares, decreasing direct ownership by 3% to 441,568 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 326d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya was granted 1,145 shares, increasing direct ownership by 0.85% to 136,646 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 326d
  PRESIDENT AND CEO Domzalski David was granted 8,681 shares, increasing direct ownership by 2% to 454,244 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 388d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 8,399 shares, decreasing direct ownership by 7% to 118,493 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 388d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 6,044 shares, decreasing direct ownership by 5% to 122,593 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 388d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 8,828 shares, decreasing direct ownership by 6% to 135,501 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 388d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 30,498 shares, decreasing direct ownership by 6% to 445,563 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 457d
  SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Stuart Iain

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 457d
  SEC Form 4 filed by CHIEF FINANCIAL OFFICER Zeronda Tyler

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 457d
  SEC Form 4 filed by CHIEF LEGAL OFFICER AND GC Harsch Mutya

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 457d
  SEC Form 4 filed by PRESIDENT AND CEO Domzalski David

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 464d
  Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 478d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 4,857 shares, decreasing direct ownership by 4% to 128,637 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 478d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 4,675 shares, decreasing direct ownership by 4% to 126,892 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 478d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 24,536 shares, decreasing direct ownership by 5% to 476,061 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 478d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 4,697 shares, decreasing direct ownership by 3% to 144,329 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 498d
  SEC Form 4 filed by Director Borowski Christine

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 498d
  SEC Form 4 filed by Director Lepore Patrick G

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 498d
  SEC Form 4 filed by Director Basta Steven L

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 498d
  SEC Form 4 filed by Director Sandoval Elisabeth

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 498d
  SEC Form 4 filed by Director Barbari Sharon

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 498d
  SEC Form 4 filed by Director Bruno Anthony D

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 508d
  PRESIDENT AND CEO Domzalski David was granted 3,901 shares, increasing direct ownership by 0.79% to 500,597 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 570d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 84 shares, decreasing direct ownership by 0.06% to 131,567 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 570d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.08% to 133,494 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 570d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 685 shares, decreasing direct ownership by 0.14% to 496,696 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 570d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 105 shares, decreasing direct ownership by 0.07% to 149,026 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 661d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 138 shares, decreasing direct ownership by 0.10% to 133,603 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 661d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 92 shares, decreasing direct ownership by 0.07% to 131,651 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 661d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 935 shares, decreasing direct ownership by 0.19% to 497,654 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 661d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 143 shares, decreasing direct ownership by 0.10% to 149,131 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 690d
  Domzalski David was granted 4,429 shares, increasing direct ownership by 0.90% to 498,589 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 752d
  Zeronda Tyler covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.07% to 131,743 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 752d
  Stuart Iain covered exercise/tax liability with 157 shares, decreasing direct ownership by 0.12% to 133,741 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 752d
  Harsch Mutya covered exercise/tax liability with 161 shares, decreasing direct ownership by 0.11% to 149,274 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 752d
  Domzalski David covered exercise/tax liability with 1,004 shares, decreasing direct ownership by 0.20% to 494,160 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 843d
  Zeronda Tyler covered exercise/tax liability with 93 shares and was granted 62,500 shares, increasing direct ownership by 90% to 131,837 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 843d
  Stuart Iain was granted 62,500 shares and covered exercise/tax liability with 157 shares, increasing direct ownership by 87% to 133,898 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 843d
  Harsch Mutya was granted 62,500 shares and covered exercise/tax liability with 161 shares, increasing direct ownership by 72% to 149,435 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 843d
  Domzalski David was granted 225,000 shares and covered exercise/tax liability with 1,004 shares, increasing direct ownership by 83% to 495,164 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 843d
  SEC Form 4 filed by Sandoval Elisabeth

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)